Molecules of senescent glial cells differentiate Alzheimer’s disease from ageing

Background Ageing is a major risk factor for Alzheimer’s disease (AD), which is accompanied by cellular senescence and thousands of transcriptional changes in the brain. Objectives To identify the biomarkers in the cerebrospinal fluid (CSF) that could help differentiate healthy ageing from neurodegenerative processes. Methods Cellular senescence and ageing-related biomarkers were assessed in primary astrocytes and postmortem brains by immunoblotting and immunohistochemistry. The biomarkers were measured in CSF samples from the China Ageing and Neurodegenerative Disorder Initiative cohort using Elisa and the multiplex Luminex platform. Results The cyclin-dependent kinase inhibitors p16/p21-positive senescent cells in human postmortem brains were predominantly astrocytes and oligodendrocyte lineage cells, which accumulated in AD brains. CCL2, YKL-40, HGF, MIF, S100B, TSP2, LCN2 and serpinA3 are biomarkers closely related to human glial senescence. Moreover, we discovered that most of these molecules, which were upregulated in senescent glial cells, were significantly elevated in the AD brain. Notably, CSF YKL-40 (β=0.5412, p<0.0001) levels were markedly elevated with age in healthy older individuals, whereas HGF (β=0.2732, p=0.0001), MIF (β=0.33714, p=0.0017) and TSP2 (β=0.1996, p=0.0297) levels were more susceptible to age in older individuals with AD pathology. We revealed that YKL-40, TSP2 and serpinA3 were useful biomarkers for discriminating patients with AD from CN individuals and non-AD patients. Discussion Our findings demonstrated the different patterns of CSF biomarkers related to senescent glial cells between normal ageing and AD, implicating these biomarkers could identify the road node in healthy path off to neurodegeneration and improve the accuracy of clinical AD diagnosis, which would help promote healthy ageing.

[1]  F. Gao,et al.  A combination model of AD biomarkers revealed by machine learning precisely predicts Alzheimer's dementia: China Aging and Neurodegenerative Initiative (CANDI) study , 2022, Alzheimer's & dementia : the journal of the Alzheimer's Association.

[2]  W. Flier,et al.  Blood-based biomarkers for Alzheimer's disease: towards clinical implementation , 2021, The Lancet Neurology.

[3]  P. Hegyi,et al.  Macrophage migration inhibitory factor as a diagnostic and predictive biomarker in sepsis: meta-analysis of clinical trials , 2021, Scientific Reports.

[4]  M. Khazaei,et al.  Hepatocyte Growth Factor-Preconditioned Neural Progenitor Cells Attenuate Astrocyte Reactivity and Promote Neurite Outgrowth , 2018, Frontiers in Cellular Neuroscience.

[5]  D. Baker,et al.  Cellular senescence in ageing: from mechanisms to therapeutic opportunities , 2020, Nature Reviews Molecular Cell Biology.

[6]  J. Del-Aguila,et al.  Chi3l1/YKL-40 is controlled by the astrocyte circadian clock and regulates neuroinflammation and Alzheimer’s disease pathogenesis , 2020, Science Translational Medicine.

[7]  Y. Zu,et al.  MIF as a biomarker and therapeutic target for overcoming resistance to proteasome inhibitors in human myeloma. , 2020, Blood.

[8]  G. Bitan,et al.  CNS-Derived Blood Exosomes as a Promising Source of Biomarkers: Opportunities and Challenges , 2020, Frontiers in Molecular Neuroscience.

[9]  F. C. Bennett,et al.  Immune cell regulation of glia during CNS injury and disease , 2020, Nature Reviews Neuroscience.

[10]  C. Schmitt,et al.  Cellular Senescence: Defining a Path Forward , 2019, Cell.

[11]  S. O'Bryant.  Blood Biomarkers for Use in Alzheimer Disease-Moving From "If" to "How?" , 2019, JAMA neurology.

[12]  D. Varges,et al.  Plasma YKL-40 in the spectrum of neurodegenerative dementia , 2019, Journal of Neuroinflammation.

[13]  Manolis Kellis,et al.  Single-cell transcriptomic analysis of Alzheimer’s disease , 2019, Nature.

[14]  M. Gorospe,et al.  Senolytic therapy alleviates Aβ-associated oligodendrocyte progenitor cell senescence and cognitive deficits in an Alzheimer’s disease model , 2019, Nature Neuroscience.

[15]  Evan Z. Macosko,et al.  Single‐Cell RNA Sequencing of Microglia throughout the Mouse Lifespan and in the Injured Brain Reveals Complex Cell‐State Changes , 2019, Immunity.

[16]  Simone Lista,et al.  Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic , 2018, Nature Reviews Neurology.

[17]  F. Llorens,et al.  YKL40 in sporadic amyotrophic lateral sclerosis: cerebrospinal fluid levels as a prognosis marker of disease progression , 2018, Aging.

[18]  D. Baker,et al.  Clearance of senescent glial cells prevents tau-dependent pathology and cognitive decline , 2018, Nature.

[19]  Loïc Dayon,et al.  Deep Dive on the Proteome of Human Cerebrospinal Fluid: A Valuable Data Resource for Biomarker Discovery and Missing Protein Identification. , 2018, Journal of proteome research.

[20]  C. Jack,et al.  NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease , 2018, Alzheimer's & Dementia.

[21]  Ben A. Barres,et al.  Normal aging induces A1-like astrocyte reactivity , 2018, Proceedings of the National Academy of Sciences.

[22]  Dan Chen,et al.  Macroglia-derived thrombospondin 2 regulates alterations of presynaptic proteins of retinal neurons following elevated hydrostatic pressure , 2017, PloS one.

[23]  H. Hampel,et al.  Diagnostic function of the neuroinflammatory biomarker YKL-40 in Alzheimer’s disease and other neurodegenerative diseases , 2017, Expert review of proteomics.

[24]  J. Ule,et al.  Major Shifts in Glial Regional Identity Are a Transcriptional Hallmark of Human Brain Aging , 2017, Cell reports.

[25]  H. Henry,et al.  Macrophage Migration Inhibitory Factor is Associated with Biomarkers of Alzheimer's Disease Pathology and Predicts Cognitive Decline in Mild Cognitive Impairment and Mild Dementia. , 2017, Journal of Alzheimer's disease : JAD.

[26]  S. Berger,et al.  Changes in the Transcriptome of Human Astrocytes Accompanying Oxidative Stress-Induced Senescence , 2016, Front. Aging Neurosci..

[27]  Keith A. Johnson,et al.  A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers , 2016, Neurology.

[28]  K. Blennow,et al.  Increased CSF biomarkers of angiogenesis in Parkinson disease , 2015, Neurology.

[29]  R. Bowser,et al.  Reactive astrocytes secrete lcn2 to promote neuron death , 2013, Proceedings of the National Academy of Sciences.

[30]  S. Sadiq,et al.  Cerebrospinal hepatocyte growth factor levels correlate negatively with disease activity in multiple sclerosis , 2012, Journal of Neuroimmunology.

[31]  J. Trojanowski,et al.  Astrocyte Senescence as a Component of Alzheimer’s Disease , 2012, PloS one.

[32]  J. Lawler,et al.  Molecular basis for the regulation of angiogenesis by thrombospondin-1 and -2. , 2012, Cold Spring Harbor perspectives in medicine.

[33]  S. Ingles,et al.  Genetic and epigenetic mechanisms collaborate to control SERPINA3 expression and its association with placental diseases. , 2012, Human molecular genetics.

[34]  J. Morris,et al.  The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[35]  G. Bernardi,et al.  Lysosomal β-galactosidase and β-hexosaminidase activities correlate with clinical stages of dementia associated with Alzheimer's disease and type 2 diabetes mellitus. , 2011, Journal of Alzheimer's disease : JAD.

[36]  D. Selkoe.  Alzheimer's disease. , 2011, Cold Spring Harbor perspectives in biology.

[37]  T. Greco,et al.  Quantitative mass spectrometry-based proteomics reveals the dynamic range of primary mouse astrocyte protein secretion. , 2010, Journal of proteome research.

[38]  Hae-Chul Park,et al.  Lipocalin-2 Is an Autocrine Mediator of Reactive Astrocytosis , 2009, The Journal of Neuroscience.

[39]  Judith Campisi,et al.  Senescence-Associated Secretory Phenotypes Reveal Cell-Nonautonomous Functions of Oncogenic RAS and the p53 Tumor Suppressor , 2008, PLoS biology.

[40]  E. Høgdall,et al.  YKL-40 protein expression in normal adult human tissues – an immunohistochemical study , 2007, Journal of Molecular Histology.

[41]  D. Dickson,et al.  Alpha1-antichymotrypsin, an inflammatory protein overexpressed in Alzheimer's disease brain, induces tau phosphorylation in neurons. , 2006, Brain : a journal of neurology.

[42]  J. Hell,et al.  Thrombospondins Are Astrocyte-Secreted Proteins that Promote CNS Synaptogenesis , 2005, Cell.

[43]  K. Langa,et al.  Mixed dementia: emerging concepts and therapeutic implications. , 2004, JAMA.

[44]  O. Tasaki,et al.  CHANGES IN CSF S100B AND CYTOKINE CONCENTRATIONS IN EARLY-PHASE SEVERE TRAUMATIC BRAIN INJURY , 2004, Shock.

[45]  T. Ohnishi,et al.  Increased hepatocyte growth factor level in cerebrospinal fluid in Alzheimer's disease , 2003, Acta neurologica Scandinavica.

[46]  C. Abraham.  Reactive astrocytes and alpha1-antichymotrypsin in Alzheimer's disease. , 2001, Neurobiology of aging.

[47]  M. Smith,et al.  Abnormal expression of the cell cycle regulators P16 and CDK4 in Alzheimer's disease. , 1997, The American journal of pathology.

[48]  P. Fraser,et al.  α1‐Antichymotrypsin Binding to Alzheimer Aβ Peptides Is Sequence Specific and Induces Fibril Disaggregation In Vitro , 1993 .

[49]  P. Fraser,et al.  Alpha 1-antichymotrypsin binding to Alzheimer A beta peptides is sequence specific and induces fibril disaggregation in vitro. , 1993, Journal of neurochemistry.

[50]  D. Price,et al.  α1-Antichymotrypsin is present together with the β-protein in monkey brain amyloid deposits , 1989, Neuroscience.

[51]  D. Price,et al.  Alpha 1-antichymotrypsin is present together with the beta-protein in monkey brain amyloid deposits. , 1989, Neuroscience.

[52]  JoVE Video Dataset , 2022 .